Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
Heron Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 23, 2020
Heron Therapeutics reported fiscal year 2019 executive compensation information on April 23, 2020.
In 2019, five executives at Heron Therapeutics received on average a compensation package of $3.2M, a 20% decrease compared to previous year.
Average pay of disclosed executives at Heron Therapeutics
Barry D. Quart, Chief Executive Officer, received $5.9M in total, which decreased by 2% compared to 2018. 84% of Quart's compensation, or $4.9M, was in option awards. Quart also received $307K in non-equity incentive plan, $639K in salary, as well as $8.4K in other compensation.
For fiscal year 2019, the median employee pay was $408,623 at Heron Therapeutics. Therefore, the ratio of Barry D. Quart's pay to the median employee pay was 14 to one.
John Poyhonen, Executive Vice President, Chief Commercial Officer, received a compensation package of $4.5M. 93% of the compensation package, or $4.2M, was in option awards.
Kimberly Manhard, Executive Vice President, Drug Development, earned $2.5M in 2019, a 3% increase compared to previous year.
Robert Hoffman, Chief Financial Officer, received $2M in 2019, which increases by 18% compared to 2018.
Robert H. Rosen, Former President, earned $1.1M in 2019, a 82% decrease compared to previous year.
Related executives
Barry Quart
Heron Therapeutics
Chief Executive Officer
Kimberly Manhard
Heron Therapeutics
Executive Vice President, Drug Development
John Poyhonen
Heron Therapeutics
President and Chief Commercial Officer
Robert Hoffman
Heron Therapeutics
Chief Financial Officer
Robert Rosen
Heron Therapeutics
Former President
You may also like
Source: SEC filing on April 23, 2020.